Waters Corporation (NYSE: WAT) and IMU Biosciences have formed a strategic partnership to advance an AI-powered immune ...
IMU’s AI platform unlocks unprecedented immune insights for cancer and other diseases, measuring 100M+ data points from a ...
A large body of research publications covering hematological disorders, such as acute myeloid leukemia (AML) and multiple myeloma (MM), demonstrates that measurable minimal disease (MRD) neg ...
IMU Biosciences partners with Waters to advance IMU’s AI-driven immunology platform to transform diagnosis and monitoring: London, UK Friday, June 26, 2026, 12:00 Hrs [IST] IMU ...
The SY3200™ system is one of the most innovative and versatile Flow Cytometry Research platforms available in the market. True innovation drives superior performance and versatility in the SY3200 ...
Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Fluorescent In Situ Hybridization Probe Market size & share revenue was ...
U.S. Minimal Residual Disease Testing Market is projected to reach USD 2.37 Billion by 2035, while Europe is expected to ...
The EC800 flow cytometry analyzer offers you greater versatility than any instrument in its class. The EC800 is an affordable solution for many flow cytometry applications, including immunophenotyping ...
According to MarketsandMarkets™, the Body Fluid Analysis Market is projected to grow from about USD 2.62 billion in 2026 to ...
Certified, Autologous Adipose-Derived Stem Cell Therapy Across 13 Approved Treatment Areas Using Patients’ Own Cells At the center of the clinic’s model is a single principle: deliver stem cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results